Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ABI-210
- Development stage
- Preclinical
- Lead developer
- Avirmax Biopharma
- Modality
- Gene Therapies
- Administration
- Intravitreal
01
Overview
ABI-210 is a preclinical-stage adeno-associated virus (AAV) gene therapy being developed by Avirmax Biopharma for the treatment of dry age-related macular degeneration (dAMD). The candidate utilizes Avirmax's proprietary AAV-S (synthetic) capsid technology, which is engineered to enhance gene delivery to the retina following intravitreal injection. The program aims to address the underlying pathology of dry AMD and geographic atrophy, though the specific therapeutic transgene has not been publicly disclosed. ABI-210 is designed to provide a long-term therapeutic effect through a single administration, potentially slowing or halting the progression of retinal degeneration.
Beyond the preview
Go deeper on ABI-210.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ABI-210.